1. |
Gronchi A, Blay JY, Trent JC. The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. Cancer, 2010, 116(8): 1847-1858.
|
2. |
杨显金, 陈佳慧, 杜江, 等. 胃肠道间质瘤的诊治现状与进展. 中国普外基础与临床杂志, 2014, 21(8): 1040-1045.
|
3. |
Eechoute K, Fransson MN, Reyners AK, et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res, 2012, 18(20): 5780-5787.
|
4. |
Demetri GD, Wang Y, Wehrle E, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/ metastatic gastrointestinal stromal tumors. J Clin Oncol, 2009, 27(19): 3141-3147.
|
5. |
Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist, 2008, 13 Suppl 2: 4-7.
|
6. |
Bakhtiar R, Lohne J, Ramos L, et al. High-throughput quantification of the anti-leukemia drug STI571(Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 768(2): 325-340.
|
7. |
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med, 2002, 347(7): 472-480.
|
8. |
Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet, 2004, 364(9440): 1127-1134.
|
9. |
Blanke CD, Rankin C, Demetri GD, et al. Phase Ⅲ randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol, 2008, 26(4): 626-632.
|
10. |
孙乃萍, 李健, 高静, 等. 胃肠间质瘤患者中Imatinib血药浓度与治疗疗效的相关性. 基础医学与临床, 2010, 30(12): 1329-1333.
|
11. |
Faber E, Divoká M, Skoumalová I, et al. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma, 2015: 1-6.[Epub ahead of print].
|
12. |
Farag S, Verheijen RB, Martijn Kerst J, et al. Imatinib pharmacokinetics in a large observational cohort of gastrointestinal stromal tumour patients. Clin Pharmacokinet, 2016 Jul 19.[Epub ahead of print].
|
13. |
Yoo C, Ryu MH, Ryoo BY, et al. Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure. Invest New Drugs, 2012, 30(4): 1703-1708.
|
14. |
Yoo C, Ryu MH, Kang BW, et al. Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib. J Clin Oncol, 2010, 28(9): 1554-1559.
|
15. |
National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Soft tissue sarcoma (version 1. 2015). 2015, Aug 20. Available at: http://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
|
16. |
Jang BH, Kim BW, Lim KJ, et al. A case of disseminated intra-abdominal gastrointestinal stromal tumor managed with low dose imatinib. Korean J Gastroenterol, 2015, 65(6): 366-369.
|
17. |
Yin Y, Xiang J, Tang S, et al. A lower dosage of imatinib in patients with gastrointestinal stromal tumors with toxicity of the treatment. Medicine (Baltimore), 2016, 95(49): e5488.
|